We hypothesized that while EDC1 would target the warhead drug to dysadherin expression cell, the warhead drug conjugated to a non-specific polyclonal antibody (negative control) would be less cytotoxic to thyroid cancer cells. This evidence concerns the gene FXYD5 and thyroid gland carcinoma.